SVN-114 selected for PTSD discovery programme

AI SummaryClose X

Solvonis Therapeutics plc has announced the selection of SVN-114 as the lead candidate from its SVN-SDN-14 discovery program targeting Post-Traumatic Stress Disorder (PTSD), a condition affecting over 20 million people globally with limited pharmacological treatments. Preclinical studies conducted by Evotec SE demonstrated that SVN-114 exhibits balanced modulation of serotonin, dopamine, and noradrenaline transporters, key neurotransmitters involved in mood and social behavior. This selection, agreed upon by the Company's Scientific Advisory Committee, marks a significant milestone for Solvonis' CNS discovery platform, with international patent applications filed for the novel chemistry, aiming to provide a strong intellectual property foundation for potential first-in-class or best-in-class therapeutics.

Disclaimer*

UK 100

Latest directors dealings